Lipocine Inc.

LPCN · Nasdaq · United States

Share price · LPCN

$1.52-0.52 (-25.49%) 3M

close as of 2026-11-18 · 24h delayed · vol 63K (0.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LPCN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Oct 2026-8.8%
  2. 9 Oct 2026-10.9%

    Nothing announced by LPCN that day or the session before.

  3. 8 Oct 2026-12.3%
  4. 22 Sep 2026-3.6%
  5. 2 Apr 2026-77.8%
  6. 1 Apr 2026+15.8%
  7. 13 Jan 2026+15.9%
  8. 12 Jan 2026+12.7%
  9. 31 Dec 2025+22.2%

    Nothing announced by LPCN that day or the session before.

  10. 29 Dec 2025+20.3%

    Nothing announced by LPCN that day or the session before.

Share of unusual movement by asset

For each asset, the share of LPCN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
testosterone undecanoate
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—53%
Sessions with no dated event—46%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Androgen receptor (AR)Small molecule
Male Hypogonadism
Hypogonadism

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026Approvaltestosterone undecanoateHealth Canada approves TLANDO
CA, Health Canada · Lipocine Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$2.3M$2.1M$2.6M+ $19M short-term inv.$0.7M-$1.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.2M$2.0M$5.0M+ $18M short-term inv.$2.6M-$3.0M operating cash flowreport ↗
2026-Q1$0.1M$2.8M$5.0M+ $20M short-term inv.$3.7M-$2.3M operating cash flowreport ↗
2025-Q3$0.1M$2.7M$3.9M+ $11M short-term inv.$3.2M-$3.0M operating cash flowreport ↗
2025-Q2$0.6M$2.1M$6.0M+ $12M short-term inv.$2.2M-$1.9M operating cash flowreport ↗
2025-Q1$0.1M$1.1M$3.4M+ $16M short-term inv.$1.9M-$2.0M operating cash flowreport ↗
2024-Q3—$1.6M$3.7M+ $16M short-term inv.$2.2M-$2.8M operating cash flowreport ↗
2024-Q2$0.1M$1.9M$5.5M+ $17M short-term inv.$3.1M-$2.5M operating cash flowreport ↗
2024-Q1$7.6M$2.8M$3.1M+ $22M short-term inv.—$2.4M operating cash flowreport ↗
2023-Q3-$3.1M$2.9M$4.1M+ $20M short-term inv.$6.7M-$2.6M operating cash flowreport ↗
2023-Q2—$2.5M$5.0M+ $21M short-term inv.$3.5M-$3.3M operating cash flowreport ↗
2023-Q1$0.1M$3.1M$4.8M+ $24M short-term inv.$3.9M-$3.9M operating cash flowreport ↗
2022-Q3—$2.1M$2.4M+ $32M short-term inv.$2.4M-$3.2M operating cash flowreport ↗
2022-Q2—$2.9M$5.0M+ $32M short-term inv.$2.6M-$3.0M operating cash flowreport ↗
2022-Q1—$1.9M$5.7M+ $36M short-term inv.$3.5M-$3.9M operating cash flowreport ↗
2021-Q3—$2.4M$4.5M+ $34M short-term inv.$3.1M-$7.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.0M$8.6M$5.2M+ $9.7M short-term inv.$2.4M-$9.8M operating cash flowreport ↗

Lipocine reported full-year 2025 revenue of $1.98M, down 82.3% YoY, with R&D spend of $8.58M, up 16.7% YoY. The company recorded a net loss of $9.63M, or $1.69 per diluted share, and ended the year with $5.21M in cash and equivalents; total cash, equivalents and marketable investment securities were $14.9M as of December 31, 2025, and approximately $24.7M as of March 6, 2026 following an ATM offering.

Pipeline updates included completion of the last patient visit in the Phase 3 study of LPCN 1154 for postpartum depression, with top-line results expected in early April 2026 and a potential U.S. NDA submission in mid-2026. The company also highlighted progress on LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management, and disclosed ongoing TLANDO commercialization partnerships, including a new license and supply agreement with Aché in Brazil.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$11M$7.3M$6.2M+ $15M short-term inv.—-$1.2M operating cash flowreport ↗
2023-FY-$2.9M$10M$4.8M+ $17M short-term inv.$4.1M-$12M operating cash flowreport ↗
2022-FY$0.5M$8.6M$3.1M+ $29M short-term inv.$2.7M-$12M operating cash flowreport ↗
2021-FY$16M$7.7M$3.0M+ $42M short-term inv.$0.2M-$4.4M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($596K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Patel Mahesh V. · director, Chief Executive OfficerOpen-market purchase25,000$1.60$40KForm 4
2026-11-12Patel Mahesh V. · director, Chief Executive OfficerOpen-market purchase25,000$1.58$39KForm 4
2026-09-30Higuchi John W. · directorOpen-market purchase15,970$2.23$36KForm 4
2026-09-29Higuchi John W. · directorOpen-market purchase9,037$2.15$19KForm 4
2026-09-28Higuchi John W. · directorOpen-market purchase12,561$2.16$27KForm 4
2026-08-03Grissinger Michael · directorAward / grant (derivative)2,000$2.11$4KForm 4
2026-06-29Patel Mahesh V. · director, Chief Executive OfficerAward / grant (derivative)52,781$2.49$131KForm 4
2026-06-03Ono Richard Dana · directorAward / grant (derivative)1,764$2.19$4KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 47 reporting institutions held 3.3M shares ($26.2M, 29.6% of shares outstanding).

#InstitutionSharesValue
1Ikarian Capital, LLC508,556$4.1M
2Squadron Capital Management LLC450,000$3.6M
3STEMPOINT CAPITAL LP320,840$2.6M
4Eversept Partners, LP294,989$2.4M
5Rosalind Advisors, Inc.221,616$1.8M
6VANGUARD CAPITAL MANAGEMENT LLC200,668$1.6M
7AIGH Capital Management LLC200,000$1.6M
8BOOTHBAY FUND MANAGEMENT, LLC140,487$1.1M
9Seven Fleet Capital Management LP124,942$998K
10Birchview Capital, LP111,786$893K
11BlackRock, Inc.89,272$713K
12Mink Brook Asset Management LLC66,812$534K
13GEODE CAPITAL MANAGEMENT, LLC63,135$505K
14Exome Asset Management LLC60,861$486K
15DIADEMA PARTNERS LP50,000$400K